Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity

Documenti analoghi

• Extracellular vesicle‐packaged lncRNA from cancer‐associated fibroblasts promotes immune evasion by downregulating HLA‐A in pancreatic cancer
  di: Hanming Yao, et al.
  Pubblicazione: (2024)
• PlexinA1 (PLXNA1) as a novel scaffold protein for the engineering of extracellular vesicles
  di: Hang Zhao, et al.
  Pubblicazione: (2024)
• Direct delivery of immune modulators to tumour‐infiltrating lymphocytes using engineered extracellular vesicles
  di: Xiabing Lyu, et al.
  Pubblicazione: (2025)
• Extracellular vesicles as human therapeutics: A scoping review of the literature
  di: Clorinda Fusco, et al.
  Pubblicazione: (2024)
• Synthetic biology‐based bacterial extracellular vesicles displaying BMP‐2 and CXCR4 to ameliorate osteoporosis
  di: Han Liu, et al.
  Pubblicazione: (2024)